3 news items
Autolus Therapeutics Presents Additional Data Analysis Of Pivotal Phase 2 Felix Study Of obe-cel For Adult r/r B-all In An Oral Presentation At ASCO
AUTL
31 May 24
of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL), being presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, (May 31 – June 4, 2024, Chicago).
Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO
AUTL
31 May 24
Society of Clinical Oncology (ASCO) Annual Meeting, (May 31 – June 4, 2024, Chicago). "At 21 months of median follow up, we're
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
AUTL
17 May 24
will be presented in oral and poster presentations at the American Society of Clinical Oncology annual meeting (ASCO – May 31 – June 4, 2024
- Prev
- 1
- Next